Business
Capricor is a biotechnology company focused on cell and exosome-based therapeutics, led by Deramiocel for Duchenne muscular dystrophy complications.
Capricor lost all FY2025 revenue and burned $72.7M of FCF while Deramiocel awaited a new FDA action date.
The read at a glance✓ Audited against SEC data
- Business mix — DMD cell therapyNote
- Revenue — $0 vs $22.3MWatch
- Net income — -$105.0M, worseWatch
- FCF — -$72.7M, worseWatch
- Equity — $305.8M, +110.2%OK
- Insiders — 0 purchases / 7 salesWatch
- Accounting — Altman greyNote
Where the revenue comes from
Fiscal 2024, as CAPRICOR THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Single reportable$22.3M
Leadership changes
From CAPRICOR THERAPEUTICS, INC.'s own filings, the day they're filed.
- Paul Auwaerter · director · appointmenteff. 2023-07-11
- Karimah Es Sabar · director · departureeff. 2023-07-11
- Ken Fisher Professor · Director · appointment
Latest filings
- 8-K · Company announcement2026-08-24
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CAPRICOR THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.